These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 1363761)

  • 1. [Prognostic factors in breast carcinoma with special reference to the C-erb-B2 gene: preliminary results].
    Criscuolo M; Federico M; Sabbatini R; Rossi E; Piccinini L; Trentini GP
    Pathologica; 1992; 84(1094):87-91. PubMed ID: 1363761
    [No Abstract]   [Full Text] [Related]  

  • 2. [Incidence of amplification of the C-erb B2/Her-2/neu gene in human breast cancer].
    Sellami M; Gamoudi M; Krichen K; Kharrat A; Ben Romdhane K; Maalej M
    Arch Inst Pasteur Tunis; 1991; 68(1-2):33-41. PubMed ID: 1687309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
    Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
    Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma.
    Heintz NH; Leslie KO; Rogers LA; Howard PL
    Arch Pathol Lab Med; 1990 Feb; 114(2):160-3. PubMed ID: 1967929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunohistochemical tumor markers in infiltrating ductal breast carcinoma].
    Gallegos M; González S; León A; Claure R; Goñi I; Andrade L; Duarte I
    Rev Med Chil; 1998 Oct; 126(10):1216-23. PubMed ID: 10030093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-erb-B2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis.
    Fontana X; Ferrari P; Namer M; Peysson R; Salanon C; Bussiere F
    Anticancer Res; 1994; 14(5B):2099-104. PubMed ID: 7840506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERBB2 amplification in breast cancer with a high rate of proliferation.
    Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Sigurdsson H
    Oncogene; 1991 Jan; 6(1):137-43. PubMed ID: 1671531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HER-2/neu oncogene as prognostic factor in breast carcinoma].
    Colnaghi MI
    Pathologica; 1992; 84(1094):55-6. PubMed ID: 1363757
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunohistochemical demonstration of c-erb B-2 oncoprotein expression in female breast cancer and its prognostic significance.
    Tervahauta A; Eskelinen M; Syrjänen S; Lipponen P; Pajarinen P; Syrjänen K
    Anticancer Res; 1991; 11(5):1677-81. PubMed ID: 1685075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
    Gaffey MJ; Frierson HF; Williams ME
    Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-erbB-2 amplification in node-negative human breast cancer.
    Ro JS; el-Naggar A; Ro JY; Blick M; Frye D; Fraschini G; Fritsche H; Hortobagyi G
    Cancer Res; 1989 Dec; 49(24 Pt 1):6941-4. PubMed ID: 2573424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
    Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients.
    Niewiadomska H; Mirowski M; Stempień M; Błoński JZ; Czyz W; Switalska J; Matyga E; Hanausek M; Wierzbicki R
    Neoplasma; 2000; 47(1):8-14. PubMed ID: 10870681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical assessment of tumour behaviour and patient prognosis in human breast cancer.
    Barnes DM
    Dis Markers; 1991; 9(3-4):159-65. PubMed ID: 1687522
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors.
    Erdogan S; Ergin M; Tuncer I
    Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation of c-erbB-2 oncoprotein and established prognostic factors in human breast cancer.
    Sütterlin MW; Haller A; Gassel AM; Peters K; Caffier H; Dietl J
    Anticancer Res; 2000; 20(6D):5083-8. PubMed ID: 11326673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
    McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
    Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum levels of a c-erbB-2 oncogene product in oral squamous cell carcinoma patients.
    Chen CH; Lin YS; Lin CC; Yang YH; Ho YP; Tsai CC
    J Oral Pathol Med; 2004 Nov; 33(10):589-94. PubMed ID: 15482324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.